We have released Q4 and Full Year 2024 financial results and recent business highlights. We are proud of our 2024 accomplishments, including the U.S. commercial launch in June 2024 of our medicine for certain adults with lower-risk?#MDS with transfusion-dependent anemia, achieving 80% enrollment in our Phase 3 trial in relapsed/refractory myelofibrosis, and ending the year with a solid cash position. ? Learn more: https://lnkd.in/esgyg4KW
Cancel the 500 million shares in your back pocket (or is it down to 400 million after stock options?) and this stock would bounce a dollar easily. Oh, that’s right. You don’t care about retail investors.
Probably one of the worst conference calls I have ever heard.
The market was not impressed with the review .
Stock took a big hit today, but I think there's a great opporunity here for J&J or someone similar to swoop in -- plenty of promise
A solid 4th quarter and full year 2024. I wish Wall Street would recognize the future potential of Rytelo!
Big congratulations! I can't wait to see the progress in 2025! ??
Awesome job. Only down 30% now.
Maybe the board chairman and management team should have their bonuses tied to shareholder value? What a concept? What happens when the board chairman and executive team have no skin in the game? Well, you lose 60% of your share value AFTER your drug is approved and sales start rolling in. C'mon Mr. Scarlett, your 12k purchase was peanuts. You and your team need to get some REAL skin in the game and give some props to your share holders.